Protagonist Therapeutics Reports Granting of Inducement Award
Protagonist Therapeutics (PTGX) has announced the granting of an equity inducement award to a new employee on April 15, 2025. The award, issued under the Company's Amended and Restated 2018 Inducement Plan, consists of options to purchase 20,000 shares of common stock at an exercise price of $46.95 per share, matching the closing price on Nasdaq on the grant date.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments over the subsequent three years. The award was approved by the Company's Compensation Committee and granted as a material inducement for employment in accordance with Nasdaq Marketplace Rule 5635(c)(4).
Protagonist Therapeutics (PTGX) ha annunciato la concessione di un premio azionario di incentivo a un nuovo dipendente il 15 aprile 2025. Il premio, emesso nell'ambito del Piano di Incentivazione Modificato e Ristabilito 2018 della Società, consiste in opzioni per l'acquisto di 20.000 azioni ordinarie a un prezzo di esercizio di $46,95 per azione, corrispondente al prezzo di chiusura su Nasdaq alla data di assegnazione.
Le opzioni prevedono un periodo di maturazione di quattro anni, con il 25% che matura dopo il primo anno e la restante parte che matura in rate mensili uguali nei successivi tre anni. Il premio è stato approvato dal Comitato per la Remunerazione della Società ed è stato concesso come incentivo sostanziale per l'assunzione, in conformità con la Regola 5635(c)(4) del Marketplace Nasdaq.
Protagonist Therapeutics (PTGX) ha anunciado la concesión de un premio de incentivos accionarios a un nuevo empleado el 15 de abril de 2025. El premio, otorgado bajo el Plan de Incentivos Modificado y Restablecido 2018 de la Compañía, consiste en opciones para comprar 20,000 acciones ordinarias a un precio de ejercicio de $46.95 por acción, igualando el precio de cierre en Nasdaq en la fecha de concesión.
Las opciones cuentan con un calendario de adquisición de derechos de cuatro años, con un 25% que se adquiere tras el primer año y el resto que se adquiere en cuotas mensuales iguales durante los siguientes tres años. El premio fue aprobado por el Comité de Compensación de la Compañía y otorgado como un incentivo importante para el empleo, de acuerdo con la Regla 5635(c)(4) del Mercado Nasdaq.
Protagonist Therapeutics (PTGX)는 2025년 4월 15일 신입 직원에게 주식 인센티브 보상을 부여했다고 발표했습니다. 이 보상은 회사의 수정 및 재정비된 2018년 인센티브 계획에 따라 발행되었으며, 20,000주의 보통주를 주당 $46.95의 행사가격으로 매수할 수 있는 옵션으로 구성되어 있으며, 이는 부여일 나스닥 마감가와 동일합니다.
옵션은 4년간의 권리 취득 일정이 적용되며, 첫 해 후 25%가 취득되고 나머지는 이후 3년 동안 매월 동일한 비율로 취득됩니다. 이 보상은 회사 보상위원회의 승인을 받았으며, 나스닥 시장 규칙 5635(c)(4)에 따라 고용 유인을 위한 중요한 보상으로 부여되었습니다.
Protagonist Therapeutics (PTGX) a annoncé l'octroi d'une attribution d'actions incitatives à un nouvel employé le 15 avril 2025. Cette attribution, délivrée dans le cadre du Plan d'incitation modifié et révisé de 2018 de la Société, consiste en des options d'achat de 20 000 actions ordinaires à un prix d'exercice de 46,95 $ par action, correspondant au cours de clôture du Nasdaq à la date d'attribution.
Les options sont soumises à un calendrier d'acquisition de droits sur quatre ans, avec 25 % acquis après la première année et le reste acquis par versements mensuels égaux au cours des trois années suivantes. L'attribution a été approuvée par le comité de rémunération de la Société et accordée en tant qu'incitation matérielle à l'emploi conformément à la règle 5635(c)(4) du marché Nasdaq.
Protagonist Therapeutics (PTGX) hat am 15. April 2025 die Gewährung einer Aktienanreizprämie an einen neuen Mitarbeiter bekannt gegeben. Die Prämie, die im Rahmen des geänderten und neu gefassten Anreizplans 2018 des Unternehmens ausgegeben wurde, besteht aus Optionen zum Kauf von 20.000 Aktien zum Ausübungspreis von 46,95 $ pro Aktie, entsprechend dem Schlusskurs an der Nasdaq am Tag der Gewährung.
Die Optionen unterliegen einem vierjährigen Vesting-Zeitplan, wobei 25 % nach dem ersten Jahr vesten und der verbleibende Anteil in gleichen monatlichen Raten über die folgenden drei Jahre vestet. Die Prämie wurde vom Vergütungsausschuss des Unternehmens genehmigt und als wesentlicher Anreiz für die Anstellung gemäß der Nasdaq Marketplace-Regel 5635(c)(4) gewährt.
- None.
- None.
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement award to a new employee upon his commencement of employment with the Company in accordance with the terms of his employment offer letter. The award was granted under the Company's Amended and Restated 2018 Inducement Plan, which was adopted on May 29, 2018, and amended on February 18, 2020 and February 15, 2022.
The new employee received options to purchase 20,000 shares of the Company's common stock on the Grant Date. The exercise price of the options is equal to
About Protagonist Therapeutics
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
What are the terms of PTGX's new equity inducement award granted on April 15, 2025?
How does the vesting schedule work for Protagonist Therapeutics' (PTGX) latest stock option grant?
What was the exercise price for PTGX's inducement award options issued in April 2025?
Under which plan did Protagonist Therapeutics issue its April 2025 inducement award?
